Belatacept to protect kidneys in heart transplant patients
Treatments studied
Part of Heart & circulation, Immune system & allergy, Kidney & urinary clinical trials.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and had a heart transplant at least 3 months ago
- You do not have donor-specific antibodies at the start of the study (an antibody test should be below the trial’s threshold)
- Your kidney function is poor or declining: estimated GFR is under 30 mL/min or it dropped by more than 50% since transplant
- You are Epstein-Barr virus positive on a blood test, and you received induction medicine (anti-lymphocyte serum) after transplant
- You must be able to understand the study and follow study visits and procedures; you must have signed consent
- For pregnancy-capable participants: pregnancy test must be negative and you must use effective contraception during the study and for 6 weeks after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called belatacept, which may help prevent the body from rejecting a new heart. It is given after a heart transplant, and the goal is to see if it works as well as or better than standard anti-rejection medicines.
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
This study tests a new approach to managing anti-rejection medicines after a heart transplant. It uses special blood tests to see if your immune system is calm, so doctors can safely reduce the medicines and lower side effects.
This Phase 2 trial tests daratumumab to reduce your body’s immune reaction (HLA antibodies) before a heart or heart-and-kidney transplant. It may help lower the risk of immediate, severe rejection in people who already have high antibody levels.
Hear when a new Heart Transplant Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.